Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus platinum-pemetrexed versus platinum-pemetrexed in untreated stage IV non-squamous NSCLC
NL-OMON50326Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoints: Progression-free survival and Overall survival. Started Dec 2016; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON50326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50326.